Squire Patton Boggs has advised Prescient Healthcare Group, a biopharma product and portfolio strategy firm, on its acquisition of Strategic North, a global healthcare market research and commercial strategy consultancy.
Founded in 2007, Prescient is a pharma services firm specialising in dynamic decision support and product and portfolio strategy. Prescient has a footprint in eight cities across the US, Europe and Asia and a team of more than 400 experts, partnering with 23 of the top 25 biopharmaceutical companies, the fastest-growing mid-caps and cutting-edge emerging biotechs, including some of the biggest and most innovative brands. Prescient has been a portfolio company of Bridgepoint Development Capital since 2021 and Baird Capital since 2017.
Strategic North was founded in 2010 and employs 70 executives out of its offices in the UK. It partners with a wide range of pharmaceutical companies to help them better understand how their customers make decisions in order to unlock the full potential of their brands.
Corporate partner and Head of UK Healthcare Mark Yeo and senior associate Joe Abbott in London led the Squire Patton Boggs team advising Prescient on the transaction. Mr. Yeo, who previously acted for Prescient on the investment by Baird Capital and the investment by Bridgepoint Development Capital, commented, “Our excellent cross-practice cross-office team from the Healthcare Group was delighted to support Prescient once again. Integrating Strategic North’s additional resources and skills into its global offering is a key transaction for Prescient’s planned expansion.”
The Squire Patton Boggs team included corporate associates Isabelle Sadler and Simon Watts-Morgan, corporate trainee Milena Bohn, tax partner Mark Simpson, tax senior associate Emma Perez, employment partner David Whincup, employment associates Sean Field-Walton and Alex Kelly and commercial and IP associate Sam O’Neill.